Exome
Vincent Jonchère et al.
Microsatellite instability at U2AF-binding polypyrimidic tract sites perturbs alternative splicing during colorectal cancer initiation
Genome Biology 2024, vol. 25, issue 1
doi: 10.1186/s13059-024-03340-5
Charles Bobin et al.
Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy
Clinical Cancer Research 2024, vol. 30, issue 15
doi: 10.1158/1078-0432.ccr-24-0753
Charles Bobin et al.
Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy
Clinical Cancer Research 2024, vol. 30, issue 15
doi: 10.1158/1078-0432.ccr-24-0753
Yuta Ito et al.
Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Cancer Research 2024, vol. 84, issue 13
doi: 10.1158/0008-5472.can-24-0132
Yuta Ito et al.
Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Cancer Research 2024, vol. 84, issue 13
doi: 10.1158/0008-5472.can-24-0132
Yann Loe-Mie et al.
De Novo Variants Found in Three Distinct Schizophrenia Populations Hit a Common Core Gene Network Related to Microtubule and Actin Cytoskeleton Gene Ontology Classes
Life 2024, vol. 14, issue 2
doi: 10.3390/life14020244
Aurore Pire et al.
Mutational signature, cancer driver genes mutations and transcriptomic subgroups predict hepatoblastoma survival
European Journal of Cancer 2024, vol. 200
doi: 10.1016/j.ejca.2024.113583
Gaël Nicolas et al.
Assessment of Mendelian and risk-factor genes in Alzheimer disease: A prospective nationwide clinical utility study and recommendations for genetic screening
Genetics in Medicine 2024, vol. 26, issue 5
doi: 10.1016/j.gim.2024.101082
Jill Pilet et al.
Preneoplastic liver colonization by 11p15.5 altered mosaic cells in young children with hepatoblastoma
Nature Communications 2023, vol. 14, issue 1
doi: 10.1038/s41467-023-42418-9
Marion Thibaudin et al.
First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial
Nature Medicine 2023, vol. 29, issue 8
doi: 10.1038/s41591-023-02497-z